Clinical Trials · NCT05680129
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Enrollment
- 623
- Start date
- Jan 2023
- Locations
- 1 site, China
- Primary endpoint
- Change from baseline in HbA1c